NCT04612452 (DTG-SWITCH) is a clinical trial in Hiv, sponsored by University of Bern.

Who is sponsoring NCT04612452?

NCT04612452 is sponsored by University of Bern.

What condition does NCT04612452 study?

NCT04612452 studies Hiv, Drug Resistancy, Virologic Failure.

Is NCT04612452 still recruiting?

NCT04612452 is currently completed. Last updated 24 March 2023.

Last reviewed 2023-03-24 · How we verify

NCT04612452: DTG-SWITCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART

Completed Last updated 24 March 2023

What this trial tests

trial in Hiv in 2,820 participants. Completed in 22 March 2023.

Timeline

5 November 2019

Primary endpoint
22 March 2023

22 March 2023

Quick facts

Lead sponsor	University of Bern
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,820
Start date	5 November 2019
Primary completion	22 March 2023
Estimated completion	22 March 2023
Sites	2 locations across Malawi, Zambia

Conditions studied

Hiv — all drugs for Hiv →
Drug Resistancy — all drugs for Drug Resistancy →
Virologic Failure — all drugs for Virologic Failure →

Sponsor

University of Bern

Who can join

18 and older, any sex, with Hiv or Drug Resistancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective observational cohort study of 2820 patients on first-line ART switching to a DTG-based first-line regimen, according to the standard of care. The study is conducted in Malawi and Zambia, in ART programs that participate in the IeDEA collaboration. Sequencing will be done on blood samples of patients with a viral load above 400 copies/mL to identify mutations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia.
Skrivankova VW, Huwa J, Muula G, Chiwaya GD, et al · · 2025 · cited 12× · PMID 38847281 · DOI 10.1093/cid/ciae261

Verify or expand the search:

Other recruiting trials for Hiv

Currently open trials in the same condition.

NCT06001814 — Mindfulness and Behavior Change to Improve Cardiovascular Health of Older People With HIV · NA · recruiting
NCT06999928 — Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV · NA · recruiting
NCT06006143 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 · Phase 2 · active not recruiting
NCT07076043 — Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention · Phase 4 · recruiting
NCT06389565 — Change My Story Task Shifted Mental Health Intervention · NA · recruiting

Other University of Bern trials

Trials by the same sponsor.

NCT05940662 — Cost Effectiveness of Various Implant Placement Protocols in the Esthetic Zone · Phase 4 · suspended
NCT02919163 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7) · NA · not yet recruiting
NCT02919189 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7) · NA · not yet recruiting
NCT04817592 — Characterization of the Corneal Biomechanics of Patients Treated by Corneal Lenticule Extraction for Advanced Refractive · not yet recruiting
NCT06806150 — The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04612452 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Bern
Last refreshed: 24 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04612452.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing